Printer Friendly

DISEASE DETECTION INTERNATIONAL FORMS NEW WOMEN'S HEALTH CARE COMPANY FOR O.T.C., RETAIL SALES OF PHARMACEUTICALS AND RAPID PREGNANCY TESTS

DISEASE DETECTION INTERNATIONAL FORMS NEW WOMEN'S HEALTH CARE COMPANY FOR O.T.C., RETAIL SALES OF PHARMACEUTICALS AND RAPID PREGNANCY TESTS
 IRVINE, Calif., Oct. 19 /PRNewswire/ -- Disease Detection International, Inc. (OTC Bulletin Board: DDII) announced today that the Company has formed a new women's health care company, FHC CORPORATION ("FHC"). The company was organized to develop and deliver diagnostic test kits and pharmaceutical products for medical conditions which primarily affect women, to the retail, over-the-counter, home markets. In making the announcement, H. Thad Morris, DDI's president and chief executive officer, said that FHC CORPORATION was capitalized by DDI, which will hold 50 percent of the new firm's common stock. PMR MARKETING LTD., a closely held pharmaceutical consulting firm, with exclusive rights to a new, one-step mid-stream pregnancy test, will own the other 50 percent interest in FHC. PMR LTD. transferred its interest in the new, three-minute test format and its interest in certain pharmaceutical products to treat various medical conditions primarily affecting women to FHC in exchange for DDI common stock. The market segment for pregnancy tests is currently a $147 million category in the United States and is forecasted to grow to $248 million by 1998 by Market Intelligence Research Corporation.
 Mr. Morris stated the formation of the new firm arose out of various discussions with large pharmaceutical companies and retail pharmacy chains expressing interest in marketing the Company's rapid test for pregnancy and the development of newer tests designed to predict ovulation. "We feel we have the products and expertise to participate in these markets with a large partner, however, DDI's focus in the professional diagnostic market and work on our seven-minute AIDS test really don't allow us to serve the important retail market segment.
 "Therefore, we feel DDI is better suited to concentrate on the professional market, while FHC, managed by pharmaceutical executives with 20 years' experience in the retail market, can better serve the consumer with our technology."
 Disease Detection International, Inc. will hold the exclusive marketing rights to FHC's rapid tests in the professional markets such as physicians' office labs, hospitals, universities and all areas outside the over-the-counter markets. FHC will be responsible for all sales directed to consumer markets.
 Mr. Morris stated FHC CORPORATION has named G. Dale Garlow as its president and chief executive officer and Donald P. Leach, R.Ph., as executive vice president. Mr. Garlow previously held various positions with The Upjohn Company (NYSE: UPJ) during his 20 years with the firm and served as president of Whiteworth/Towne Paulsen, a generic pharmaceutical manufacturer. Mr. Leach is a registered pharmacist and has held various executive positions with Rugby Laboratories, Quantum Pharmics division of American Home Products and Whiteworth/Towne Paulsen.
 Mr. Morris and Mr. Garlow said that they expected both firms to have products in distribution within the first quarter of 1993. Mr. Morris, speaking for DDI, stated that it will market the new pregnancy test to physicians and hospitals through its national distribution network under the tradename PRO-STEP hCG(TM). Mr. Garlow stated that FHC is currently negotiating with several potential partners for sales in the retail markets and hopes to have its negotiations completed prior to the end of the year.
 Disease Detection International, Inc. develops, manufactures and markets a family of rapid diagnostic tests in the fields of infectious and sexually transmitted diseases.
 -0- 10/19/92
 /CONTACT: H. Thad Morris, president and chief executive officer, Disease Detection International, Inc., 714-457-1787/
 (DDII) CO: Disease Detection International, Inc.; FHC CORPORATION ST: California IN: MTC SU:


JG -- NYON2 -- 1337 10/19/92 08:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1992
Words:595
Previous Article:NETWORK REPORTS FISCAL YEAR END RESULTS; OPERATIONS RESTRUCTURING COMPLETED; EXPECTS TO OBTAIN FINANCING WITHIN 45 DAYS
Next Article:XEROX INTRODUCES FULLY FEATURED PORTABLE READING MACHINE: BREAKTHROUGH FOR BLIND, VISUALLY IMPAIRED
Topics:


Related Articles
DISEASE DETECTION INTERNATIONAL REPORTS RECORD REVENUES AND PROFITS FOR FISCAL 1992 AND SIGNIFICANT FORECASTS FOR 1993 AND BEYOND
DISEASE DETECTION INTERNATIONAL INC. (DDI) ANNOUNCES BRASILIAN APPROVAL TO SELL RAPID, ON-SITE, AIDS TEST
DISEASE DETECTION INTERNATIONAL INC. SIGNS DISTRIBUTION AGREEMENTS WITH BAXTER'S SCIENTIFIC PRODUCTS DIVISION FOR ONE-STEP PREGNANCY TEST
DISEASE DETECTION INTERNATIONAL, INC., SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT FOR SEVEN-MINUTE AIDS TEST FOR ARGENTINA
DISEASE DETECTION INTERNATIONAL COMPLETES $8.7M THREE-COUNTRY, THREE- YEAR DISTRIBUTION AGREEMENTS FOR SALE OF RAPID AIDS TEST KITS IN S.A.
QUIDEL RECEIVES FDA CLEARANCE FOR DIP AND READ PREGNANCY TEST
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL REPORTS SECOND QUARTER RESULTS
QUIDEL RECEIVES FDA CLEARANCE TO MARKET THE FIRST ONE-STEP, WHOLE BLOOD, RAPID H. PYLORI TEST
QUIDEL AWARDED RAPID DIAGNOSTIC SUPPLY CONTRACT FROM AMERINET

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters